Skip to content

Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele

In Utero Endoscopic Correction of Myelomeningocele: Laparotomy Versus Percutaneous - A Pilot Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03856034
Enrollment
12
Registered
2019-02-27
Start date
2018-11-02
Completion date
2027-12-31
Last updated
2019-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chiari Malformation, Myelomeningocele, Neural Tube Defects, Spina Bifida

Keywords

spina bifida, myelomeningocele, neural tube defect, chiari malformation, fetoscopy, percutaneous, fetus

Brief summary

The purpose of this study is to evaluate the feasibility of a fetoscopic surgical technique for antenatal correction of fetal myelomeningocele. Two surgical approaches will be utilized. The percutaneous approach will be offered to participants with a posterior placenta. The laparotomy/uterine exteriorization approach will be offered to participants regardless of placental location.

Interventions

DEVICEFetoscopy

Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).

Sponsors

Wellington Hospital
CollaboratorOTHER_GOV
University of Southern California
CollaboratorOTHER
USFetus
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Myelomeningocele (including myeloschisis) at level T1 through S1 with hindbrain herniation. Lesion level and hindbrain herniation will be confirmed by MRI and ultrasonography. 2. Maternal age ≥18 years. 3. Gestational age of 19 to 27 6/7 weeks' gestation as determined by clinical information and evaluation of first ultrasound. 4. Balanced karyotype with written confirmation of culture results. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is at 24 weeks or more. 5. Positive evaluation of social work consult indicating the patient is capable of consenting to the procedure and has the appropriate social support system to participate in the study. 6. Positive evaluation from pediatric neurology consult. 7. Willing to remain in the greater Wellington or Pasadena area (within a 30-minute car ride) for remainder of the pregnancy and deliver at Wellington Regional Medical Center or Huntington Memorial Hospital for postnatal management. The participants must be willing to return to our center for the 12, 24, 30, 48, and 60 months for follow-up evaluation.

Exclusion criteria

1. Multiple gestation 2. Insulin-dependent pregestational diabetes 3. Presence of a fetal anomaly not related to myelomeningocele. A fetal echocardiogram will be conducted before surgery and if the finding is abnormal, the patient will be excluded. 4. Fetal kyphosis of 30 degrees or more, assessed by ultrasound or MRI. 5. Presence of uterine cervical cerclage or history of incompetent cervix. 6. Placenta previa or placental abruption. 7. Short cervix \< 25 mm measured by cervical ultrasound. 8. Obesity as defined by body mass index (BMI) of 35 or greater. 9. History of previous spontaneous singleton delivery prior to 37 weeks. 10. Maternal-fetal Rh isoimmunization, Kell sensitization or a history of neonatal alloimmune thrombocytopenia. 11. Maternal HIV or Hepatitis-B status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis B status is unknown, the patient must be tested and found to have negative results before she can be enrolled. 12. Known Hepatitis-C positivity. If the patient's Hepatitis C status is unknown, she does not need to be screened. 13. Uterine anomaly such as large (greater than 6 cm) fibroids, cervical fibroids or multiple fibroids or Mullerian duct abnormality. 14. Other maternal medical condition which is a contraindication to surgery or anesthesia. 15. Patient does not have a support person (e.g., husband, partner, parents). 16. Inability to comply with the travel and follow-up requirements of the study. 17. Patient does not meet psychosocial criteria as determined by the social worker evaluation. 18. Participation in another intervention study that influences maternal and fetal morbidity and mortality. 19. Maternal hypertension as determined by the investigator, which would increase the risk of preeclampsia or preterm delivery (including, but not limited to: uncontrolled hypertension, chronic hypertension with end organ damage and new onset hypertension in current pregnancy). 20. Bicornuate uterus or any other uterine malformation the PI decides is not safe for surgery. 21. Nickel allergy. 22. Maternal request to undergo open fetal surgery for the antenatal correction of open spina bifida at our institution primarily or after failed fetoscopic approach. 23. Known maternal hypersensitivity to bovine collagen or chondroitin materials.

Design outcomes

Primary

MeasureTime frameDescription
Rate of successful in-utero fetoscopic myelomeningocele closures using either laparotomy or percutaneous techniquesAt time of surgery until delivery, up to 21 weeksSuccessful fetoscopic closure of the spinal defect and reversal of hindbrain herniation as assessed by ultrasound and MRI prior to delivery

Countries

United States

Contacts

Primary ContactRuben Quintero, MD
q@the-fetal-institute.com720-753-3825
Backup ContactRamen Chmait, MD
chmait@usc.edu626-356-3360

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026